# US 2011/0301154 A1 · Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0301154 A1
- Document ID: US20110301154A1
- Status: Published application
- Kind: A1
- Application number: 13/201,271
- Filed: 2010-02-17
- Published: 2011-12-08
- Earliest claimed: 2009-02-26
- Inventors: Alexandre Vamvakides
- Web page: https://patentgrep.com/patent/US20110301154A1

## CPC

- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/365: Lactones
- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/4525: containing a five-membered ring with oxygen as a ring hetero atom
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5415: ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
- A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention involves new and original sigma receptors Ligands: (Mono-or dialkylaminoalkyl)-γ-butyro-lactones, their analogues aminotetrahydroturanes, the (1-adamantyl) benzene alkylamines, the N,N Dialkyl α-[(adamantyl-1)ben-zyloxy-2] alkylamines and the 3-cyclopentyl adamantyl-amines or alkylamines or-alkyl phenylamines, their enantiomers or di-astereoisomers, their pharmaceutically acceptable salts and Quinacrine Me-thylene blue, Astemizole and their relative analogues with pro-apoptotic and/or anti-apoptotic properties over cellular biochemical mechanisms, with prototypical anti-cancer, an-timetastatic and antiviral activities associated with antagonism of the neuropatic pain and, at very low doses, with cytoprotectve and cytoregenerative activity against the cytodegenerative diseases.

## Claims

### Claim at position 1

1-8. (canceled)

### Claim 9

A method of using sigma(σ) receptor ligands, said method comprising the steps of:
providing a compound comprising a sigma(σ)-receptor ligands and a sigma(σ) ligands generics, said sigma(σ) ligands generics being selected from the group consisting of Quinacrine, analogues of Quinacrine, Methylene blue, analogues of Methylene blue, Astemizole, and analogues of Astemizole; and
using said compound for preparation of pharmaceuticals with anticancer, antimetastatic and antiviral activity associated with analgesic properties.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said sigma(σ)-receptor ligands being selected from the group consisting of (mono- or di-alkylaminoalkyl)-γ-butyrolactones), aminotetrahydrofuranes, enantiomers or diastereoisomers of aminotetrahydrofuranes, (1-adamantyl) benzene alkylamines, enantiomers or diastereoisomers of (1-adamantyl) benzene alkylamines, N,N di-alkyl α-[(adamantyl-1) benzyloxy-2] alkylamines, enantiomers or diastereoisomers of N,N di-alkyl α-[(adamantyl-1) benzyloxy-2] alkylamines, 3-cyclopentyl adamantyl-amines or -alkylamines or -alkyl phenylamines, enantiomers or diastereoisomers of 3-cyclopentyl adamantyl-amines or -alkylamines or -alkyl phenylamines, and their pharmaceutically acceptable salts.

### Claim 11 (depends on 10)

The method according to claim 10, wherein said compound further comprising at least one pharmaceutically acceptable excipient.

### Claim 12

A method of using sigma(σ) receptor ligands, said method comprising the steps of:
providing a compound comprising a sigma(σ)-receptor ligands and a sigma(σ) ligands generics, said sigma(σ) ligands generics being selected from the group consisting of Quinacrine, analogues of Quinacrine, Methylene blue, analogues of Methylene blue, Astemizole, and analogues of Astemizole; and
using said compound for preparation of pharmaceuticals with analgesic activity against neuropathic pain.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said sigma(σ)-receptor ligands being selected from the group consisting of (mono- or di-alkylaminoalkyl)-γ-butyrolactones), aminotetrahydrofuranes, enantiomers or diastereoisomers of aminotetrahydrofuranes, (1-adamantyl) benzene alkylamines, enantiomers or diastereoisomers of (1-adamantyl) benzene alkylamines, N,N di-alkyl α-[(adamantyl-1) benzyloxy-2] alkylamines, enantiomers or diastereoisomers of N,N di-alkyl α-[(adamantyl-1) benzyloxy-2] alkylamines, 3-cyclopentyl adamantyl-amines or -alkylamines or -alkyl phenylamines, enantiomers or diastereoisomers of 3-cyclopentyl adamantyl-amines or -alkylamines or -alkyl phenylamines, and their pharmaceutically acceptable salts.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said compound further comprising at least one pharmaceutically acceptable excipient.

### Claim 15

A method of using sigma(σ) receptor ligands, said method comprising the steps of:
providing a compound comprising a sigma(σ)-receptor ligands and a sigma(σ) ligands generics, said sigma(σ) ligands generics being selected from the group consisting of Quinacrine, analogues of Quinacrine, Methylene blue, analogues of Methylene blue, Astemizole, and analogues of Astemizole; and
using said compound for preparation of pharmaceuticals selected from the group consisting of pharmaceuticals acting synergistically with clinically used anticancer drugs and antagonizing neuropathic pain induced by the anticancer drugs, pharmaceuticals with cytoprotective activity against pathogenesis of cytodegenerative diseases, pharmaceuticals with cytoprotective and cytoregenerative activity, and pharmaceuticals with protective activity against the pathogenesis of inflammatory and neuropathic pain.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said sigma(σ)-receptor ligands being selected from the group consisting of (mono- or di-alkylaminoalkyl)-γ-butyrolactones), aminotetrahydrofuranes, enantiomers or diastereoisomers of aminotetrahydrofuranes, (1-adamantyl) benzene alkylamines, enantiomers or diastereoisomers of (1-adamantyl) benzene alkylamines, N,N di-alkyl α-[(adamantyl-1) benzyloxy-2] alkylamines, enantiomers or diastereoisomers of N,N di-alkyl α-[(adamantyl-1) benzyloxy-2] alkylamines, 3-cyclopentyl adamantyl-amines or -alkylamines or -alkyl phenylamines, enantiomers or diastereoisomers of 3-cyclopentyl adamantyl-amines or -alkylamines or -alkyl phenylamines, and their pharmaceutically acceptable salts.

### Claim 17 (depends on 16)

The method according to claim 16, wherein said compound further comprising at least one pharmaceutically acceptable excipient.
